Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on November 19, 2026, disclosing the exercise of 5,410 stock options and the sale of 5,370 shares of common stock on November 18, 2026, described as the final trades under a pre-arranged 10b5-1 trading plan.
Key Highlights
- Final plan trades: According to the filing, the transactions reported are "the final trades" under a 10b5-1 plan adopted by Rothblatt on November 7, 2025.
- Options exercised: 5,410 stock options were exercised at a conversion price of $117.76 per share via transaction code M, held indirectly by trust.
- Shares sold: A total of 5,370 shares were disposed of across 16 separate sale transactions on November 18, 2026, at weighted average prices ranging from $570.8167 to $586.735 per share.
- Remaining beneficial ownership: Following all reported transactions, Rothblatt's indirect trust holding of the shares involved in these trades stood at 324,443 shares, with additional holdings reported directly (40,513 shares), by spouse (166 shares), and in other trusts (249,108, 45,596, and 8,902 shares).
- Stock options extinguished: The 5,410 stock options held indirectly by trust, with an expiration date of March 15, 2027, show 0.00 remaining following the exercise.
- Indirect ownership structure: Shares are held in family trusts "as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries," according to the filing.
Rothblatt's November 18 Option Exercise and Multi-Tranche Share Sales at United Therapeutics
According to the Form 4 filed with the SEC, Martine A. Rothblatt, serving as both Chairperson and CEO of United Therapeutics Corp, carried out a series of transactions on November 18, 2026. The filing states that the exercise of 5,410 stock options at $117.76 per share and the subsequent sale of shares were executed pursuant to a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The filing explicitly notes these were "the final trades under this plan."
The 5,370 shares disposed of were sold across 16 separate tranches, with weighted average prices reported from $570.8167 to $586.735 per share. Individual tranche sizes ranged from 40 shares to 909 shares. The filing notes that multiple tranches were each executed across sub-ranges of prices, and Rothblatt "hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected" for each such tranche.
All transactions involved shares held indirectly through family trusts. Following the reported activity, the trust position tied to these transactions reflected 324,443 shares of common stock. Rothblatt also reported direct ownership of 40,513 shares, 166 shares held indirectly by spouse, and additional indirect trust holdings of 249,108 shares, 45,596 shares, and 8,902 shares, as listed separately in the filing's beneficial ownership table.
What Was Disclosed
The filing disclosed the exercise of 5,410 stock options and the sale of 5,370 common shares by Rothblatt on November 18, 2026, conducted under a 10b5-1 plan adopted November 7, 2025, described as the plan's final transactions, with all activity through indirect family trust holdings.


Please wait processing your request...